Amphstar Pharmaceuticals, Inc.
TypePublic
HeadquartersRancho Cucamonga, California, United States
Key people
  • Mary Z. Luo
  • (Chairman of the Board)
  • Jack Yongfeng Zhang
  • (CEO)
RevenueIncrease US$ 498.9 million (2022)
Increase US$ 107.4 million (2022)
Increase US$ 91.3 million (2022)
Total assetsIncrease US$ 741.9 million (2022)
Total equityIncrease US$ 528.6 million (2022)
Number of employees
1,615
WebsiteAmphastar.com
Footnotes / references
[1]

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[3]

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]

In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[6][7]

See also

References

  1. ↑ "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved July 31, 2023.
  2. ↑ "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  3. ↑ "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
  4. 1 2 Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
  5. ↑ Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.
  6. ↑ "Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash". Yahoo Finance. Retrieved 2023-04-26.
  7. ↑ "Amphastar buys Baqsimi to build out specialty med offering". www.thepharmaletter.com. Retrieved 2023-04-26.
  • Official website
  • Business data for Amphstar Pharmaceuticals, Inc.:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.